Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05383339Recruiting
Testing blood markers in autoimmune, vasculitis, and autoinflammation
This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.
Paris, FranceAges 18 years+ - NCT05388006RecruitingPhase 2
Testing three medicines for Richter transformation in CLL/SLL
This Phase 2 trial studies acalabrutinib, venetoclax, and durvalumab together for Richter transformation (a more aggressive lymphoma) that developed from CLL or SLL. The goal is to improve how well treatment works and how long people can respond.
Palo Alto, CaliforniaAges 18 years+ - NCT05388331Recruiting
Study of silent brain lesions seen on MRI
This study follows people who have silent white-matter spots on brain MRI that may be related to nerve insulation problems (demyelination). It aims to better understand what these findings mean and whether they point to a specific condition.
NiceAges Any age - NCT05390424Recruiting
Test dried blood spots for hepatitis and HIV
This study checks blood from a simple dried blood spot to screen for hepatitis B, hepatitis C, and HIV. It may help find infections early, which can allow earlier treatment.
AvranchesAges 18 years+ - NCT05391100Recruiting
Screening people with rheumatoid arthritis for lung scarring
This study looks for early lung scarring in people who have rheumatoid arthritis. It may help find a serious lung condition earlier so doctors can watch or treat it sooner.
BudapestAges 40 years+ - NCT05391061Recruiting
Cibinqo tablet study for moderate-to-severe atopic dermatitis
This study looks at Cibinqo (an oral medicine) in people with moderate-to-severe atopic dermatitis (eczema) who are already going to start it under their clinician’s standard care plan. It may help doctors learn about how the medicine works and fits into real-world treatment.
SeoulAges 12 years+ - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT05394363Recruiting
Victoria children birth-cohort study with parent/guardian consent
This study follows children born in a specific 2-year window and their parents or guardians over time. It helps researchers understand how children and families change as they grow, which can guide future health supports in Victoria.
Parkville, VictoriaAges 1 day+ - NCT05394922Recruiting
Study of sugar patterns in lupus anti-DNA antibodies
This study looks at the “sugar coating” on anti-DNA antibodies in people with lupus. The goal is to better understand these antibody patterns, which may help improve how lupus is studied or treated in the future.
MontpellierAges 18–80 - NCT05395689RecruitingPhase 3
Dust mite allergy vaccine for ongoing runny nose and asthma
This Phase 3 study tests Beltavac®, a treatment aimed at dust mite allergies, to see if it can improve persistent nasal allergy symptoms and help people whose asthma is also affected. You may be a good match if you have confirmed dust mite sensitization and ongoing moderate-to-severe symptoms.
Orihuela, AlicanteAges 12–65 - NCT05395624RecruitingPhase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson
This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.
San Francisco, CaliforniaAges 18–80 - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT05403177Recruiting
Share your cancer data and samples for Ontario research
This study collects and combines medical records, genetic (genomic) data, and tumor/blood samples from people with cancer. It helps researchers build and improve a large “gold standard” cancer dataset that can support future studies and better understanding of cancer.
Kingston, OntarioAges 18 years+ - NCT05404958Recruiting
Improve how HIV prevention and treatment services are integrated
This study looks at ways to better connect HIV prevention services with HIV treatment services in participating clinics. It mainly involves interviewing clinic leaders and staff, plus public health staff, to learn what’s working and how to improve care.
MombasaAges Any age - NCT05405387RecruitingPhase 2
Budesonide to prevent serious diarrhea after stem cell transplant
This Phase 2 study tests whether budesonide can lower the chance of moderate-to-severe diarrhea in people with multiple myeloma who are getting an autologous stem cell transplant. It may help your comfort and reduce complications during the transplant recovery period.
Salt Lake City, UtahAges 18 years+ - NCT05413759Recruiting
Helping rheumatoid arthritis patients take medicines on schedule
This study looks at how well people with rheumatoid arthritis (RA) take their RA medicines—especially medicines like methotrexate and other targeted or biologic treatments. It may help improve medication adherence (taking doses correctly) and supports safer, more consistent treatment at home.
Pierre-Bénite, LyonAges 18 years+ - NCT05414409RecruitingPhase 2
Gut microbiome study in young people with type 1 diabetes
This Phase 2 study looks at the gut microbiome (the bacteria in your intestines) in youth with type 1 diabetes, and how metformin may work differently through the gut. It may help researchers understand mechanisms and future treatment options.
Indianapolis, IndianaAges 11–18 - NCT05417165RecruitingPhase 2
Pneumococcal vaccine plan for CLL or SLL patients
This Phase 2 study tests a specific plan for giving a pneumococcal vaccine in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may help improve protection against pneumococcal infections in patients who have not started CLL/SLL treatment yet.
Columbus, OhioAges 18 years+ - NCT05418010RecruitingPhase 2
Natalizumab treatment for early multiple sclerosis-like symptoms
This Phase 2 study tests natalizumab to treat people who have had a first episode of symptoms suggestive of multiple sclerosis. It aims to see whether the treatment can help after early “demyelination” changes are seen on brain MRI.
LondonAges 18–55 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55 - NCT05420935Recruiting
Study of antibodies after operating-room allergic reactions
This study looks at different kinds of allergy-related antibodies in people who had an allergic reaction during surgery. The goal is to better understand what immune signals are involved so future allergy prevention and care can improve.
Paris, ParisAges 18–70 - NCT05421325RecruitingPhase 2
Vaccine-like immune treatment to prevent lung infections in seniors
This Phase 2 study tests a site-specific immune “booster” in people age 65 and older to help improve natural immunity and reduce respiratory (lung/airway) infections. You may be eligible if you can consent, are in an eligible living situation, and are not currently using certain immune-suppressing medicines.
Burnaby, British ColumbiaAges 65 years+ - NCT05422027RecruitingPhase 1/Phase 2
Selinexor with VRd for high-risk newly diagnosed myeloma
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
Guangzhou, GuangdongAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.